Epizyme (NASDAQ:EPZM) reported Q1 EPS of ($0.38), $0.03 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $8.7 million versus the consensus estimate of $10.42 million.
Epizyme (NASDAQ:EPZM) reported Q1 EPS of ($0.38), $0.03 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $8.7 million versus the consensus estimate of $10.42 million.